Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. (Rigel), incorporated in June 1996, is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company has product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Type
Public
HQ
South San Francisco, US
Founded
1996
Employees
126 (est)-21%
Rigel Pharmaceuticals was founded in 1996 and is headquartered in South San Francisco, US

Key People at Rigel Pharmaceuticals

James M. Gower

James M. Gower

CEO
Frank Torti

Frank Torti

Investor
Raul R. Rodriguez

Raul R. Rodriguez

President, COO
Elliott B. Grossbard

Elliott B. Grossbard

EVP, Development CMO

Rigel Pharmaceuticals Locations

South San Francisco, US

Rigel Pharmaceuticals Metrics

Rigel Pharmaceuticals Summary

Market capitalization

$237 M

Closing share price

$2.39
Rigel Pharmaceuticals's current market capitalization is $237 M.

Rigel Pharmaceuticals Market Value History

Rigel Pharmaceuticals Online Presence

Rigel Pharmaceuticals News

Rigel Pharmaceuticals Company Life

You may also be interested in